CollPlant Biotechnologies Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CollPlant Biotechnologies Ltd.
Trials In Focus: A Call For Incentives To Help Drive Trial Diversity
Panelists at the BIO CEO & Investor meeting talked about ways to improve trial diversity. Also, GSK and Pfizer released retrospective analyses of diversity in their trials, while J&J is working to improve diversity with Stand Up To Cancer.
REMS Vendor Disruptions Prompt Greater US FDA Scrutiny
McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.
Trials In Focus: Walmart Joins Growing List Of Retailers Entering Clinical Research
SIGA provides an update on its monkeypox program, while Massive Bio announces progress on its AI platform for connecting cancer patients to trials, with additional updates from BridgeBio, the Oncology Institute, and CROs Caidya, Charles River Labs, Syneos Health and PPD parent Thermo Fisher Scientific.
VBI Poised To Take On GSK, Dynavax As Hep B Vaccination Market Takes Off
VBI Vaccines obtained FDA approval of its three-antigen hepatitis B vaccine PreHevbrio and will take on GSK’s Engerix-B and Dynavax’s Heplisav-B as CDC recommends universal HBV immunization.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Natural Products
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.